Tambocor Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Flecainide acetate

Indications/Uses

AV nodal reciprocating tachycardia, arrhythmias associated w/ Wolff-Parkinson-White syndrome & similar conditions w/ accessory pathway. Paroxysmal atrial fibrillation in patients w/ disabling symptoms. Symptomatic sustained ventricular tachycardia. Premature ventricular contractions &/or nonsustained ventricular tachycardia which are causing disabling symptoms, where these are resistant to other therapy or when other treatment has not been tolerated. Maintenance of normal rhythm following conversion by other means.

Click to view Tambocor detailed prescribing information

Dosage/Direction for Use

Adult Supraventricular arrhythmias Initially 50 mg bd, if required may be increased to max: 300 mg daily. Ventricular arrhythmias Initially 1 tab bd, max: 400 mg daily. Renal impairment (CrCl ≤35 mL/min/1.73 m²) Max initial dose: 1 tab daily or 50 mg bd.

Click to view Tambocor detailed prescribing information

Overdosage

View Tambocor overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Cardiac failure, patients w/ history of MI who have either asymptomatic ventricular ectopics or nonsustained ventricular tachycardia. Long-standing atrial fibrillation w/ no attempt to convert to sinus rhythm, haemodynamically significant valvular heart disease. Sinus nodal dysfunction, atrial conduction defects, 2nd degree or greater AV block, bundle branch or distal block unless pacing rescue is available.

Click to view Tambocor detailed prescribing information

Special Precautions

Not to be administered to patients w/ existing poor thresholds or non-programmable pacemakers. Patients w/ permanent pacemakers or temporary pacing electrodes; predisposition to cardiac failure; acute onset of atrial fibrillation following cardiac surgery. Frequent monitoring of plasma level. Correct electrolyte disturbances before treatment. Renal & hepatic impairment. Pregnancy & lactation. Not recommended in childn <12 yr. Elderly.

Click to view Tambocor detailed prescribing information

Use In Pregnancy & Lactation

Click to view Tambocor detailed prescribing information

Adverse Reactions

Most commonly, giddiness, dizziness, lightheadedness, visual disturbances, nausea & vomiting. Proarrhythmia may occur in patients w/ structural heart disease &/or significant left ventricular impairment.

Click to view Tambocor detailed prescribing information

Drug Interactions

May cause rise in plasma digoxin. Possible additive -ve inotropic effects of β-blockers & other cardiac depressants. Enhanced elimination by enzyme inducers. Closely monitor for adverse effects w/ amiodarone. Not recommended w/ other Na-channel blockers.

Click to view Tambocor detailed prescribing information

Storage

View Tambocor storage conditions for details to ensure optimal shelf-life.

Description

View Tambocor description for details of the chemical structure and excipients (inactive components).

Action

View Tambocor mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Cardiac Drugs

ATC Classification

C01BC04 - flecainide ; Belongs to class Ic antiarrhythmics.

Regulatory Classification

Presentation/Packing

Form

Tambocor tab 100 mg

Packing/Price

60's

Tambocor

flecainide

Manufacturer:

iNova

Distributor:

Zuellig Pharma